{"lc": {"ivermectin-can-kill-covid-19-within-48-hours-monash-university-study-finds": {"story_link": "https://www.thepharmaletter.com/article/ivermectin-can-kill-covid-19-within-48-hours-monash-university-study-finds", "user_code": "GOLD_19", "age_group": "31_40", "agreed": true, "close_date_time": "2021-10-24 18:47:12", "close_timestamp": 1637779632479, "created": "24/11/2021 18:47:14", "department": "Institute of Creative and Cultural Entrepreneurship", "disability": false, "ease": 4, "environment": "production", "experiment_date_datepicker": "2021-11-24", "gender": "female", "id": "10940248-d85b-4f40-8cef-683828d92b16", "open_date_time": "2021-10-24 18:38:5", "open_timestamp": 1637779085169, "story_date": "2020-04-21 00:00:00", "story_source": "tpl", "story_title": "Ivermectin can kill COVID-19 within 48 hours', Monash University study finds", "summary": "This article talked about how Monash University conducted an antiviral research and found that Ivermectin to be effective in inhibiting and stopping viruses like Covid-19. It was led by Dr Kylie Wagstaff, whom claims that Ivermectin was used to test on cells and that it works in killing covid-19 within 48 hours. ", "task_condition": "viz", "task_key": "ivermectin-can-kill-covid-19-within-48-hours-monash-university-study-finds", "task_level": "post_graduate_ma_msc", "time_taken_in_seconds": 547310, "what": "How Ivermectin can kill covid-19 within 48 hours, Dr Kylie Wagstaff claims that studies show Ivermectin stop viruses and that it works. ", "when_happened": "few_years_ago", "where_location": "Monash University, Research centre", "who": "Monash University, people, Dr Kylie Wagstaff", "why": "Kills Covid-19, stops viruses, inhibits and stops virus in the body"}, "challenges-expected-for-novavax-covid-19-vaccine-in-usa": {"story_link": "https://www.thepharmaletter.com/article/challenges-expected-for-novavax-covid-19-vaccine-in-usa", "user_code": "GOLD_19", "age_group": "31_40", "agreed": true, "close_date_time": "2021-10-24 19:10:35", "close_timestamp": 1637781035280, "created": "24/11/2021 19:10:36", "department": "Institute of Creative and Cultural Entrepreneurship", "disability": false, "ease": 4, "environment": "production", "experiment_date_datepicker": "2021-11-24", "gender": "female", "id": "4892cdc7-1697-474a-8f33-c13daf224bd3", "open_date_time": "2021-10-24 18:57:40", "open_timestamp": 1637780260489, "story_date": "2021-06-23 00:00:00", "story_source": "tpl", "story_title": "Challenges expected for Novavax' COVID-19 vaccine in USA", "summary": "The article talks about Novavax, the US vaccines developer , have developed and tested their new vaccine , NVX-CoV2373. NVX-CoV2373 have produced positive results, proving its effectiveness against covid19, especially among the participants who have contracted the alpha and beta variants of covid19. \r\nHowever, NVX-CoV2373 has not been tested on people with the delta variant yet. More tests are being conducted at the moment. ", "task_condition": "text", "task_key": "challenges-expected-for-novavax-covid-19-vaccine-in-usa", "task_level": "post_graduate_ma_msc", "time_taken_in_seconds": 774791, "what": "How the NVX-CoV2373 have generated positive results in it's tests with the Prevent-19 trial population , How NVX-CoV2373 has not been tested with people with the delta variant yet but have proved effective against the alpha and beta variants", "when_happened": "few_month_ago", "where_location": "USA, Novavax testing/research sites", "who": "Novavax , USA, countries who have more urgent need of covid19 vaccine, Mexico trial population, Alpha, beta, delta variants,PREVENT-19 trial population, GlobalData", "why": "Possible vaccine against covid19 , once the vaccine is approved, it will be used globally , how the test results have proved to be effective against covid19 virus"}, "australian-gps-urged-to-prescribe-ivermectin-triple-therapy-to-fight-covid-19": {"story_link": "https://www.thepharmaletter.com/article/australian-gps-urged-to-prescribe-ivermectin-triple-therapy-to-fight-covid-19", "user_code": "GOLD_19", "age_group": "31_40", "agreed": true, "close_date_time": "2021-10-24 18:57:29", "close_timestamp": 1637780249554, "created": "24/11/2021 18:57:31", "department": "Institute of Creative and Cultural Entrepreneurship", "disability": false, "ease": 4, "environment": "production", "experiment_date_datepicker": "2021-11-24", "gender": "female", "id": "9194419c-29f9-48a0-be45-499caa3079f8", "open_date_time": "2021-10-24 18:47:23", "open_timestamp": 1637779643067, "story_date": "2020-08-20 00:00:00", "story_source": "tpl", "story_title": "Australian GPs urged to prescribe ivermectin triple therapy to fight COVID-19", "summary": "Professor Borody strongly believes that Australia should be adopting a triple ivermectin therapy method. He believes that GPs should be granted permission to prescribe ivermectin to their patients in order to help combat the symptoms caused by Covid19. From his own experience and based on international data, he cited an almost 100% cure rate and symptom improvement within four to six days. He believes that Australia should take a more proactive role in fighting covid19. ", "task_condition": "text", "task_key": "australian-gps-urged-to-prescribe-ivermectin-triple-therapy-to-fight-covid-19", "task_level": "post_graduate_ma_msc", "time_taken_in_seconds": 606487, "what": "Dr Borody and his view about prescribing triple ivermectin therapy to patients, how Australia should be adopting a 'war room' mentality when it comes to tackling Covid19, How Ivermectin show an improve in symptoms and rise in cure rate", "when_happened": "few_years_ago", "where_location": "Australia", "who": "Thomas Borody , Australia, Australia government, GPs, Ivermectin , Australian politicians,US Food and Drug Administration and Therapeutics Goods Administration, ", "why": "Possible cure for Covid-19, a good option to combat symptoms of Covid19, Ivermectin as a good track record in terms of cure rates and improve covid19 symptoms"}, "japan-is-first-country-to-approve-covid-19-cocktail-ronapreve": {"story_link": "https://www.thepharmaletter.com/article/japan-is-first-country-to-approve-covid-19-cocktail-ronapreve", "user_code": "GOLD_19", "age_group": "31_40", "agreed": true, "close_date_time": "2021-10-24 18:37:54", "close_timestamp": 1637779074761, "created": "24/11/2021 18:37:56", "department": "Institute of Creative and Cultural Entrepreneurship", "disability": false, "ease": 4, "environment": "production", "experiment_date_datepicker": "2021-11-24", "gender": "female", "id": "fbdd842e-0957-48fd-82c5-1f3e5c62997d", "open_date_time": "2021-10-24 18:27:15", "open_timestamp": 1637778435376, "story_date": "2020-07-21 00:00:00", "story_source": "tpl", "story_title": "Japan is first country to approve COVID-19 cocktail Ronapreve", "summary": "I believe the article talks about the rise in emerging variants, infections and deaths. It also talks about how Japan is trying to suggest treatments and new options in order to combat this problem. Japan has introduced and approve of a new Covid-19 cocktail called Ronapreve, which is possibly a combination of antibodies which could possibly lower the symptoms caused by the deadly Delta variant. Ronapreve might prove to be slightly risky, however it has been tested at leading pharmaceutical organisations. ", "task_condition": "viz", "task_key": "japan-is-first-country-to-approve-covid-19-cocktail-ronapreve", "task_level": "post_graduate_ma_msc", "time_taken_in_seconds": 639385, "what": "Covid infection, treatments and options that Japan has, authorising the use of the cocktail Ronapreve, how to reduce infection rates, how many deaths it has caused, risk of the new treatment/product", "when_happened": "few_month_ago", "where_location": "Japan, hospital ", "who": "Japan, patients, government, people, Dr Osamu Okuda, president", "why": "emerging variants, deaths, risks"}}, "tb": {"pfizer": {"story_term": "pfizer", "user_code": "GOLD_19", "age_group": "31_40", "agreed": true, "close_date_time": "2021-10-24 19:41:0", "close_timestamp": 1637782860607, "created": "24/11/2021 19:41:02", "department": "Institute of Creative and Cultural Entrepreneurship", "disability": false, "ease": 3, "environment": "production", "experiment_date_datepicker": "2021-11-24", "gender": "female", "id": "b7829f19-343a-4c1e-868f-0cc5f7a4eff2", "open_date_time": "2021-10-24 19:28:37", "open_timestamp": 1637782117681, "summary": "Researchers at Public Health England (PHE) have tested the Pfizer vaccine and seen positive results of 88% protection against the B.1.617.2 variant two weeks after a second dose. Pfizer proved to be more effective compared to AstraZeneca which tested at 60% against the strain after two weeks. \r\n\r\nIn May 2021, UK\u00e2\u0080\u0099s Medicines and Healthcare products Regulatory Agency (MHRA) approved new storage conditions for the COVID-19 vaccine from Pfizer. It can now be stored at normal fridge temperatures for up to 31 days and it can be used in a wider range of healthcare settings. This would give patients greater access to the Pfizer vaccine. \r\n\r\nBased on clinical data proving safety and efficacy in this age group, the US Centers for Disease Control and Prevention (CDC) have also announced that it will be approving the use of the Pfizer vaccine in adolescents. The US believes that in doing so, they are strengthening their nation\u00e2\u0080\u0099s efforts to protect even more people from the effects of COVID-19. ", "task_condition": "text", "task_key": "pfizer", "task_level": "post_graduate_ma_msc", "time_taken_in_seconds": 742926}, "astrazeneca": {"story_term": "astrazeneca", "user_code": "GOLD_19", "age_group": "31_40", "agreed": true, "close_date_time": "2021-10-24 19:28:21", "close_timestamp": 1637782101749, "created": "24/11/2021 19:28:23", "department": "Institute of Creative and Cultural Entrepreneurship", "disability": false, "ease": 3, "environment": "production", "experiment_date_datepicker": "2021-11-24", "gender": "female", "id": "cfdac05e-5ce2-4cf4-8cb9-704948791034", "open_date_time": "2021-10-24 19:10:53", "open_timestamp": 1637781053836, "summary": "AstraZeneca was the first global pharmaceutical company to join COVAX in June 2020 in line with the company\u00e2\u0080\u0099s shared commitment to global, equitable access to vaccines. It started shipping it out to various countries, with its aim of supplying a total of 142 countries with hundreds of millions of doses of the vaccine. \r\n\r\nIn the first quarter of 2021, AstraZeneca delivered significant revenue growth of 15% in the quarter to $7,320 million, excluding the contribution from the COVID-19 vaccine. Having delivered one of the most important vaccines in history, AstraZeneca  is predicted to continue it's high performance for the rest of the year. \r\n\r\nEven though there were reports of AstraZeneca causing unusual blood clots in patients with low blood platelets, the benefits still outweigh the risks. AstraZeneca have lowered the death rates caused by covid19 and kept people out of hospitals. ", "task_condition": "viz", "task_key": "astrazeneca", "task_level": "post_graduate_ma_msc", "time_taken_in_seconds": 1047913}}}